• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于 DNA 骨架的层级自组装构建智能类细胞型前药用于抑制乳腺癌肺转移

Fabricating an intelligent cell-like nano-prodrug via hierarchical self-assembly based on the DNA skeleton for suppressing lung metastasis of breast cancer.

机构信息

Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing 211198, P. R. China.

出版信息

Biomater Sci. 2019 Aug 20;7(9):3652-3661. doi: 10.1039/c9bm00630c.

DOI:10.1039/c9bm00630c
PMID:31169833
Abstract

Cancer metastasis is a major cause of high mortality in breast cancer. Despite the progress achieved in nanomaterial-based treatments, the cure rate remains unsatisfactory, owing to their poor biocompatibility and non-specific recognition. Inspired by the cell-mimetic strategy, in this work, we fabricated an intelligent cell-like nano-prodrug (Dox-MPK@MDL) for lung metastasis of breast cancer. Specifically, a DNA tetrahedron dendrimer was selected to act as a rigid internal cytoskeleton, and then sequentially coated with a liposome and macrophage membrane to form cell-like Dox-MPK@MDL via hierarchical self-assembly. Here, it should be noted that pH-sensitive Dox-MPK prodrugs were synthesized and inserted into the DNA-based cytoskeleton (the Dox group is an intercalator of double stranded DNA) in advance for the next anti-metastatic therapy. Our results show that Dox-MPK@MDL specifically targeted the sites of lung metastasis via the biomimetic metastasis-homing effects and intelligently triggered Dox release at the metastatic cancer cells, thereby leading to the significant inhibition of lung metastasis. All these features help to enhance the anti-metastatic therapy efficiency of Dox while maximally reducing side-effects.

摘要

癌症转移是导致乳腺癌高死亡率的主要原因。尽管基于纳米材料的治疗方法取得了进展,但由于其生物相容性差和非特异性识别,治愈率仍不尽如人意。受细胞模拟策略的启发,在这项工作中,我们制备了一种用于乳腺癌肺转移的智能细胞样纳米前药(Dox-MPK@MDL)。具体来说,选择一种 DNA 四面体型树状大分子作为刚性内部细胞骨架,然后通过分级自组装,依次用脂质体和巨噬细胞膜包覆,形成细胞样 Dox-MPK@MDL。值得注意的是,我们预先合成了 pH 敏感的 Dox-MPK 前药并插入基于 DNA 的细胞骨架中(Dox 基团是双链 DNA 的嵌入剂),以便进行下一步的抗转移治疗。我们的研究结果表明,Dox-MPK@MDL 通过仿生转移归巢效应特异性靶向肺转移部位,并在转移性癌细胞中智能触发 Dox 释放,从而显著抑制肺转移。所有这些特征都有助于提高 Dox 的抗转移治疗效率,同时最大限度地减少副作用。

相似文献

1
Fabricating an intelligent cell-like nano-prodrug via hierarchical self-assembly based on the DNA skeleton for suppressing lung metastasis of breast cancer.基于 DNA 骨架的层级自组装构建智能类细胞型前药用于抑制乳腺癌肺转移
Biomater Sci. 2019 Aug 20;7(9):3652-3661. doi: 10.1039/c9bm00630c.
2
Acid-sensitive lipidated doxorubicin prodrug entrapped in nanoemulsion impairs lung tumor metastasis in a breast cancer model.载酸敏脂质体阿霉素前药的纳米乳可抑制乳腺癌模型肺转移。
Nanomedicine (Lond). 2017 Aug;12(15):1751-1765. doi: 10.2217/nnm-2017-0091. Epub 2017 Jul 13.
3
Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers.载顺铂和阿霉素前药的协同组合化疗:谷胱甘肽和 pH 敏感的纳米载体。
Drug Des Devel Ther. 2020 Nov 25;14:5205-5215. doi: 10.2147/DDDT.S260253. eCollection 2020.
4
Human serum albumin-based doxorubicin prodrug nanoparticles with tumor pH-responsive aggregation-enhanced retention and reduced cardiotoxicity.基于人血清白蛋白的阿霉素前药纳米粒具有肿瘤 pH 响应性聚集增强的滞留和降低的心脏毒性。
J Mater Chem B. 2020 May 6;8(17):3939-3948. doi: 10.1039/d0tb00327a.
5
Biomimetic theranostic strategy for anti-metastasis therapy of breast cancer via the macrophage membrane camouflaged superparticles.仿生诊疗一体化策略通过巨噬细胞膜伪装超粒子实现乳腺癌的抗转移治疗。
Mater Sci Eng C Mater Biol Appl. 2020 Oct;115:111097. doi: 10.1016/j.msec.2020.111097. Epub 2020 May 14.
6
Active-targeting and acid-sensitive pluronic prodrug micelles for efficiently overcoming MDR in breast cancer.主动靶向和酸敏感的两亲性前药胶束用于有效克服乳腺癌的多药耐药性。
J Mater Chem B. 2020 Apr 1;8(13):2726-2737. doi: 10.1039/c9tb02328c.
7
Activatable Fluorescence Imaging and Targeted Drug Delivery via Extracellular Vesicle-Like Porous Coordination Polymer Nanoparticles.通过细胞外囊泡样多孔配位聚合物纳米粒子实现的可激活荧光成像和靶向药物递送。
Anal Chem. 2019 Nov 5;91(21):14036-14042. doi: 10.1021/acs.analchem.9b03679. Epub 2019 Oct 17.
8
Chitosan Immobilization on Bio-MOF Nanostructures: A Biocompatible pH-Responsive Nanocarrier for Doxorubicin Release on MCF-7 Cell Lines of Human Breast Cancer.壳聚糖固定在生物 MOF 纳米结构上:一种用于人类乳腺癌 MCF-7 细胞系的阿霉素释放的生物相容 pH 响应性纳米载体。
Inorg Chem. 2018 Nov 5;57(21):13364-13379. doi: 10.1021/acs.inorgchem.8b01955. Epub 2018 Oct 17.
9
Synergistic action of doxorubicin and 7-Ethyl-10-hydroxycamptothecin polyphosphorylcholine polymer prodrug.多柔比星与 7-乙基-10-羟基喜树碱聚磷酸胆碱聚合物前药的协同作用。
Colloids Surf B Biointerfaces. 2020 May;189:110741. doi: 10.1016/j.colsurfb.2019.110741. Epub 2020 Feb 1.
10
Reversing the undesirable pH-profile of doxorubicin via activation of a di-substituted maleamic acid prodrug at tumor acidity.通过在肿瘤酸性环境中激活二取代马来酰胺酸前药来逆转阿霉素不良的pH分布特征。
Chem Commun (Camb). 2017 Nov 28;53(95):12826-12829. doi: 10.1039/c7cc06843c.

引用本文的文献

1
Targeting circulating tumor cell‒neutrophil interactions: nanoengineered strategies for inhibiting cancer metastasis.靶向循环肿瘤细胞与中性粒细胞的相互作用:抑制癌症转移的纳米工程策略
J Nanobiotechnology. 2025 Jun 17;23(1):449. doi: 10.1186/s12951-025-03522-8.
2
Advancements in Cell Membrane-Derived Biomimetic Nanotherapeutics for Breast Cancer.用于乳腺癌的细胞膜衍生仿生纳米疗法的进展
Int J Nanomedicine. 2025 May 12;20:6059-6083. doi: 10.2147/IJN.S502144. eCollection 2025.
3
Macrophage membrane-functionalized nanotherapeutics for tumor targeted therapy.
用于肿瘤靶向治疗的巨噬细胞膜功能化纳米疗法
Theranostics. 2025 Mar 31;15(10):4823-4847. doi: 10.7150/thno.108875. eCollection 2025.
4
In Vivo Interactions of Nucleic Acid Nanostructures With Cells.核酸纳米结构与细胞的体内相互作用
Adv Mater. 2025 Jan;37(2):e2314232. doi: 10.1002/adma.202314232. Epub 2024 Sep 12.
5
Nanotechnology for the theranostic opportunity of breast cancer lung metastasis: recent advancements and future challenges.用于乳腺癌肺转移诊疗机会的纳米技术:最新进展与未来挑战。
Front Bioeng Biotechnol. 2024 May 31;12:1410017. doi: 10.3389/fbioe.2024.1410017. eCollection 2024.
6
Biomimetic Nano-Drug Delivery System: An Emerging Platform for Promoting Tumor Treatment.仿生纳米药物传递系统:促进肿瘤治疗的新兴平台。
Int J Nanomedicine. 2024 Jan 18;19:571-608. doi: 10.2147/IJN.S442877. eCollection 2024.
7
Lipid-hybrid cell-derived biomimetic functional materials: A state-of-the-art multifunctional weapon against tumors.脂质杂交细胞衍生的仿生功能材料:对抗肿瘤的前沿多功能武器。
Mater Today Bio. 2023 Aug 3;22:100751. doi: 10.1016/j.mtbio.2023.100751. eCollection 2023 Oct.
8
Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis.用于治疗癌症转移的基于免疫细胞膜的仿生纳米药物
Acta Pharm Sin B. 2023 Jun;13(6):2464-2482. doi: 10.1016/j.apsb.2023.03.004. Epub 2023 Mar 8.
9
Metastatic Breast Cancer: Review of Emerging Nanotherapeutics.转移性乳腺癌:新兴纳米疗法综述
Cancers (Basel). 2023 May 25;15(11):2906. doi: 10.3390/cancers15112906.
10
Macrophage cell membrane-based nanoparticles: a new promising biomimetic platform for targeted delivery and treatment.基于巨噬细胞膜的纳米粒子:一种用于靶向递药和治疗的新型有前途的仿生平台。
J Nanobiotechnology. 2022 Dec 27;20(1):542. doi: 10.1186/s12951-022-01746-6.